Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 5Gynecologic 3Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Peritoneal Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Pharmacogenomic Variants × Gynecologic × Clear all
NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
25 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03756818 2023-02-28

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
52 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡